FREZENT Biological Solutions
Eliminating the threat of recurrent cancer.
- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2017
- Website
- frezent.com
- Total Funding
- $100K
- Last Round
- $100K Pre-Seed
About
FREZENT Biological Solutions is a New York-based preclinical oncology therapeutics company founded by Dr. Natasha Shtraizent and Dr. Lina Freage-Kahn. Its mission is to eliminate the threat of recurrent cancer by developing novel bispecific antibodies and biological inhibitors targeting cancer-specific lipid metabolism pathways. The company focuses on extending lives of advanced-stage cancer patients by targeting dormant cancer cells that drive recurrence. FREZENT was selected for the 2025 MSK Therapeutics Accelerator cohort at Memorial Sloan Kettering Cancer Center.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account